Condition: Cataract Extraction · Sponsor: Laboratorios Sophia S.A de C.V.
The main objective of this study is to evaluate the efficacy and safety of the PRO-232 formulation manufactured by Laboratorios Sophia S.A. de C.V. on the ocular surface of postoperative cataract patients versus a concomitant administration of ophthalmic moxifloxacin and dexamethasone.
This description comes directly from the study's public registry record.
Oscar Olvera-Montaño, MD · 3330004200 · oscar.olvera@sophia.com.mx
Alejandra Sánchez-Ríos, MD · 3330004200 · alejandra.sanchez@sophia.com.mx
Always discuss trial participation with your own doctor first.
| Retina Center | Tijuana, Estado de Baja California, Mexico | Recruiting |
| RGH Integra | Puebla City, Puebla, Mexico | Recruiting |
Get one email when the public record changes — results posted, or the study's status changes. Nothing else, ever.
We email about this public record only. Unsubscribe anytime with one click. Never medical advice.
This page is independently generated by Eichor from the public ClinicalTrials.gov record and re-synced daily. It is not the sponsor's official website unless claimed. Nothing here is medical advice; eligibility is always determined by the study team — talk to your own doctor first.
Source record: clinicaltrials.gov/study/NCT07305987